Prostate Cancer

Last fall, Myovant’s prostate cancer drug outshone the standard of care at keeping patients’ testosterone levels down, a phase 3 showing that teed up an FDA filing. Now, as the agency ponders the case, the company is unveiling data for patients with metastatic disease—and they’re not so rosy. The company pitted the drug, relugolix, against the standard of care, leuprolide, in 934 patients with advanced prostate cancer. Nearly all patients taking relugolix (97%) kept their testosterone levels down over 48 weeks, compared with 89% of patients taking leuprolide, Myovant reported last November. However, the drug staved off cancer progression at about the same rate as the incumbent in a subgroup of patients whose cancer had spread beyond the prostate, the new data show. After 48 months, 74% of metastatic patients on relugolix were castration resistance-free, compared with 75% of patients on leuprolide. Prostate cancer that is castration-resistant keeps growing even when the amount of tes

Sponsored Content by GENYOUth One of the most troubling outcomes of the pandemic is its impact on school meals. With 30M students depending on federal meal programs, school closures have put school meal delivery/distribution at risk. Before COVID-19, 1 in 6 kids was food insecure; now it’s 1 in 4. The meals crisis underscores the role schools play in strengthening kids’ lives, particularly vulnerable students who face inequities due to socioeconomic status, race and ethnicity.

IMAGE:  Prostate cancer is the second most frequent cancer in men worldwide. view more  Credit: MedUni Wien/Houdek (Vienna, 29 September 2020) An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal European Urology . The study showed that overall survival was 2 - 3 times higher than in the placebo arm. Ipilimumab is a humanised monoclonal IgG1 antibody that is active against CTLA-4. CTLA-4 is a molecule that controls part of the immune system by down-regulating it. "Cancer cells can evade the endogenous defence of the immune system by deactivating it. An antibody that targets CTLA-4, a so-called checkpoint inhibitor (CPI), can block this deactivation, thereby reactivating the immune system once again. This reactivated immune response can then he

A new drug application (NDA) has been submitted to the FDA for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen (PSMA), for the imaging of prostate cancer through the use of positron emission tomography, according to an announcement from Telix Pharmaceuticals Limited.1 The application for the product is comprised of clinical findings collected from over 600 patients who participated in prospective and retrospective clinical trials that were conducted by Telix Pharmaceuticals or in collaboration. The NDA is also based on definitive peer-reviewed clinical research that had been conducted at the University of California, Los Angeles (UCLA), the Peter MacCallum Cancer Centre, and Heidelberg University Hospital. “We are pleased to have achieved this significant milestone with the submission of the first commercial NDA for PSMA imaging in the United States,” Bernard Lambert, MD, president of Telix Pharmaceuticals USA, stated in a press rel

Support the news September 25, 2020 Shanahan rings the “Good Luck Bell” to celebrate the last day of treatment. (MARK SHANAHAN) The story of a Boston Globe reporter who decided to document his life with prostate cancer via a new — and very personal — podcast.    Guests Mark Shanahan , entertainment reporter at the Boston Globe. Host of the podcast "Mr. 80 Percent." (@MarkAShanahan) Dr. Mark Pomerantz , oncologist at The Dana-Farber Cancer Institute. Tom Farrington , president and founder of The Prostate Health Education Network. Interview Highlights On the prevalence of this “absurdly common” disease Mark Shanahan : Doctors like to say that most men will either die with prostate cancer or from it. 1 in 9 men are diagnosed in their lifetime with prostate cancer, but many more men have it and don't know it. Prostate cancer is extremely treatable, we should say, an extremely treatable disease, and very slow growing. I don't want to say — I was n

By: Gaudencio Olgin, MD Robotic and Minimally Invasive Urologic Surgeon Robotics Program Medical Director at DHR Health Prostate cancer is the second most common cancer among men, affecting 1 in 9 men in their lifetime, and the second leading cause of cancer death in men after lung cancer. As a man ages, his chances of being diagnosed with prostate cancer increases. Men at an increased risk are African-American or have a first degree relative (father, brother, son) who has been diagnosed with this malignancy. The prostate is a golf ball sized gland found only in men that is located underneath the bladder and in front of the rectum. It surrounds the urine tube that carries urine from the bladder to and through the penis. Since prostate growth is a natural process of aging, men may experience urinary symptoms such as weakened urinary flow and more frequent trips to the bathroom. These types of symptoms may also be seen in prostate cancer. In general, there are NO signs specific t

By: Gaudencio Olgin, MD Robotic and Minimally Invasive Urologic Surgeon Robotics Program Medical Director at DHR Health Prostate cancer is the second most common cancer among men, affecting 1 in 9 men in their lifetime, and the second leading cause of cancer death in men after lung cancer. As a man ages, his chances of being diagnosed with prostate cancer increases. Men at an increased risk are African-American or have a first degree relative (father, brother, son) who has been diagnosed with this malignancy. The prostate is a golf ball sized gland found only in men that is located underneath the bladder and in front of the rectum. It surrounds the urine tube that carries urine from the bladder to and through the penis. Since prostate growth is a natural process of aging, men may experience urinary symptoms such as weakened urinary flow and more frequent trips to the bathroom. These types of symptoms may also be seen in prostate cancer. In general, there are NO signs specific t

By: Gaudencio Olgin, MD Robotic and Minimally Invasive Urologic Surgeon Robotics Program Medical Director at DHR Health Prostate cancer is the second most common cancer among men, affecting 1 in 9 men in their lifetime, and the second leading cause of cancer death in men after lung cancer. As a man ages, his chances of being diagnosed with prostate cancer increases. Men at an increased risk are African-American or have a first degree relative (father, brother, son) who has been diagnosed with this malignancy. The prostate is a golf ball sized gland found only in men that is located underneath the bladder and in front of the rectum. It surrounds the urine tube that carries urine from the bladder to and through the penis. Since prostate growth is a natural process of aging, men may experience urinary symptoms such as weakened urinary flow and more frequent trips to the bathroom. These types of symptoms may also be seen in prostate cancer. In general, there are NO signs specific t

Dazed, I step inside and drop my bag. Without even saying hello, Michelle takes my face in her hands and kisses me. Like, really kisses me. This is new, I think. I don’t know where the children are. If I have to guess, they’ve been sent away with clear instructions not to return any time soon. Still without a word, Michelle leads me up the stairs and into our bedroom. We won’t leave for hours. Thus began the Year of Sex, an unbridled romp that put a merciful end to our long trek across the conjugal tundra. Like many couples, Michelle and I had succumbed to the middle-age cliché of a sex-lite marriage. We raised the kids, focused on work, paid the cable bill, and dutifully changed the oil every 3,000 miles. Advertisement This was a return to our early days. Michelle and I met in college and started living together in our 20s. For a few years, we bunked above a pottery studio in rural Maine, a tiny village with a gas station, a post office, a cemetery, and the distinction of being